Your browser doesn't support javascript.
loading
Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization.
Katopodi, Theodora; Petanidis, Savvas; Anestakis, Doxakis; Charalampidis, Charalampos; Chatziprodromidou, Ioanna; Floros, George; Eskitzis, Panagiotis; Zarogoulidis, Paul; Koulouris, Charilaos; Sevva, Christina; Papadopoulos, Konstantinos; Dagher, Marios; Karakousis, Vasileios Alexandros; Varsamis, Nikolaos; Theodorou, Vasiliki; Mystakidou, Chrysi Maria; Vlassopoulos, Konstantinos; Kosmidis, Stylianos; Katsios, Nikolaos Iason; Farmakis, Konstantinos; Kosmidis, Christoforos.
Affiliation
  • Katopodi T; Department of Medicine, Laboratory of Medical Biology and Genetics, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Petanidis S; Department of Medicine, Laboratory of Medical Biology and Genetics, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Anestakis D; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Charalampidis C; Department of Anatomy, Medical School, University of Cyprus, Nicosia, Cyprus.
  • Chatziprodromidou I; Department of Anatomy, Medical School, University of Cyprus, Nicosia, Cyprus.
  • Floros G; Department of Public Health, Medical School, University of Patra, Patra, Greece.
  • Eskitzis P; Department of Electrical and Computer Engineering, University of Thessaly, Volos, Greece.
  • Zarogoulidis P; Department of Obstetrics, University of Western Macedonia, Kozani, Greece.
  • Koulouris C; Third Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Sevva C; Third Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Papadopoulos K; Third Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Dagher M; Third Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Karakousis VA; Third Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Varsamis N; Third Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Theodorou V; Department of Surgery, Interbalkan Medical Center, Thessaloniki, Greece.
  • Mystakidou CM; Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Vlassopoulos K; Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Kosmidis S; Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Katsios NI; Department of Medicine, Medical University of Plovdiv, Plovdiv, Bulgaria.
  • Farmakis K; Medical School, Faculty of Health Sciences, University of Ioannina, Ioannina, Greece.
  • Kosmidis C; Pediatric Surgery Clinic, General Hospital of Thessaloniki "G. Gennimatas", Aristotle University of Thessaloniki, Thessaloniki, Greece.
Front Immunol ; 14: 1325360, 2023.
Article in En | MEDLINE | ID: mdl-38292487
ABSTRACT
A significant factor in the antitumor immune response is the increased metabolic reprogramming of immunological and malignant cells. Increasing data points to the fact that cancer metabolism affects not just cancer signaling, which is essential for maintaining carcinogenesis and survival, but also the expression of immune cells and immune-related factors such as lactate, PGE2, arginine, IDO, which regulate the antitumor immune signaling mechanism. In reality, this energetic interaction between the immune system and the tumor results in metabolic competition in the tumor ecosystem, limiting the amount of nutrients available and causing microenvironmental acidosis, which impairs the ability of immune cells to operate. More intriguingly, different types of immune cells use metabolic reprogramming to keep the body and self in a state of homeostasis. The process of immune cell proliferation, differentiation, and performance of effector functions, which is crucial to the immune response, are currently being linked to metabolic reprogramming. Here, we cover the regulation of the antitumor immune response by metabolic reprogramming in cancer cells and immune cells as well as potential strategies for metabolic pathway targeting in the context of anticancer immunotherapy. We also discuss prospective immunotherapy-metabolic intervention combinations that might be utilized to maximize the effectiveness of current immunotherapy regimes.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Metabolic Reprogramming / Neoplasms Type of study: Observational_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: Grecia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Metabolic Reprogramming / Neoplasms Type of study: Observational_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: Grecia